This week on the FLATLINING Podcast, Matthew and Ron discuss the new weight loss drug by Novo Nordisk ($NVO ) called Wegovy and how it and similar drugs could change America’s public health. Plus, they talk about why insurance companies aren’t covering it and how and when that could change. Subscribe to the FLATLINING Podcast on Apple Podcasts, Spotify, the iHeartRadio app, Amazon Music, Google Podcasts, Stitcher, Pandora, TuneIn, and Audible. Articles mentioned in this program: Ozempic Can Cause Major Weight Loss. What Happens if You Stop Taking It? - The New York TimesWhat to Know About Ozempic, Wegovy and the New Weight-Loss Market - CNETCovering new weight loss drugs could strain Medicare, policy experts warn - STAT News This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.flatlining.net
Ep. 43 - The hype behind Wegovy
www.flatlining.net
The FLATLINING Podcast from Fulcrum Strategies
The FLATLINING Podcast from Fulcrum Strategies brings you great healthcare news analysis and discussion each week from industry experts who know their way around politics, economics, and a doctor’s office. Questions about payor issues, Medicaid expansion, or the No Surprises Act? We’ve got you covered. New episodes drop every Wednesday morning.
The FLATLINING Podcast from Fulcrum Strategies brings you great healthcare news analysis and discussion each week from industry experts who know their way around politics, economics, and a doctor’s office. Questions about payor issues, Medicaid expansion, or the No Surprises Act? We’ve got you covered. New episodes drop every Wednesday morning.Listen on
Substack App
RSS Feed
Appears in episode
Fulcrum Strategies
Recent Episodes
Ep. 43 - The hype behind Wegovy